US OptionsDetailed Quotes
SNX241220C185000
- 0.00
- 0.000.00%
15min DelayClose Nov 22 09:30 ET
0.00High0.00Low
0.00Open0.00Pre Close0 Volume0 Open Interest185.00Strike Price0.00Turnover0.00%IV55.70%PremiumDec 20, 2024Expiry Date0.00Intrinsic Value100Multiplier27DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma69.89Leverage Ratio--Theta--Rho--Eff Leverage--Vega
TD Synnex Stock Discussion
Sign in to post a comment
Hedge fund managers are adjusting their sails in the stock market, redirecting investments from mega-cap technology firms to a diverse array of companies poised to benefit from the artificial intelligence (AI) revolution, a new report from $Goldman Sachs (GS.US)$ reveals.
An analysis of 707 hedge funds, with a mighty $2.7 trillion in equity positions, has highlighted a strategic shift in their stock holdings in 2024 Q1. Thes...
An analysis of 707 hedge funds, with a mighty $2.7 trillion in equity positions, has highlighted a strategic shift in their stock holdings in 2024 Q1. Thes...
37
2
TD SYNNEX's high beta suggests potential future buying opportunity. Current share price, trading around industry multiples, seems to factor in optimistic future growth.
1
Morning Movers
Gapping up
$Estee Lauder (EL.US)$ Shares soared over 3% following an upgrade to buy from neutral by Bank of America, which referenced the company's profitability recovery efforts, new products, and growing market share in the prestige beauty sector.
$Allstate (ALL.US)$ The insurance stock climbed 0.9% after HSBC raised its rating to buy from hold, with analyst Vikram Gandhi commending the company's "decisive management...
Gapping up
$Estee Lauder (EL.US)$ Shares soared over 3% following an upgrade to buy from neutral by Bank of America, which referenced the company's profitability recovery efforts, new products, and growing market share in the prestige beauty sector.
$Allstate (ALL.US)$ The insurance stock climbed 0.9% after HSBC raised its rating to buy from hold, with analyst Vikram Gandhi commending the company's "decisive management...
20
TD SYNNEX's earnings potential is considered to be at least as good as it seems, and possibly even better, despite the impact of unusual items. The improvement in EPS over the last three years is a positive sign.
TD SYNNEX's revenue growth is expected to slow, with the forecast 2.1% annualised growth rate until the end of 2024 being well below the historical 29% p.a. growth over the last five years and the industry's expected revenue growth of 5.2% annually.
Insider selling at TD SYNNEX is seen as a negative sign, implying a lower price is reasonable. High insider ownership could suggest the company operates in all shareholders' interest. The absence of insider buying in the past year and recent selling calls for caution.
Insiders at TD SYNNEX possibly consider shares overvalued, given recent sell-offs. Despite no insider purchases, the company's profitability and growth ease some concern, though insider selling poses a worry.
Here are the top gap ups and downs for the stocks with a market cap above $5 billion after market closed (gaps range from large to small):
Gap Ups
1. $Korea Electric Power (KEP.US)$ - up 3.7%
2. $Unity Software (U.US)$ - up 2.9%
3. $NetEase (NTES.US)$ - up 1.7%
4. $Banco Santander (SAN.US)$ - up 1.5%
5. $Kellanova (K.US)$ - up 1.5%
6. $Saia (SAIA.US)$ - up 0.9%
7. $Prudential (PUK.US)$ - up 0.9%
8. $Logitech International (LOGI.US)$ - up 0...
Gap Ups
1. $Korea Electric Power (KEP.US)$ - up 3.7%
2. $Unity Software (U.US)$ - up 2.9%
3. $NetEase (NTES.US)$ - up 1.7%
4. $Banco Santander (SAN.US)$ - up 1.5%
5. $Kellanova (K.US)$ - up 1.5%
6. $Saia (SAIA.US)$ - up 0.9%
7. $Prudential (PUK.US)$ - up 0.9%
8. $Logitech International (LOGI.US)$ - up 0...
+13
10
1
Gainers:
• $Kezar Life Sciences (KZR.US)$ +92% (announces positive top line results from the MISSION Phase 2 trial)
• $Sutro Biopharma (STRO.US)$ +24.5% (Sutro Biopharma and Astellas to collaborate to advance novel immunostimulatory antibody-drug conjugates)
• $Ceragon (CRNT.US)$ +17.7% (AVNW to acquire all shares of CRNT that it does not already own for $2.80/sh)
• $Trip.com (TCOM.US)$ +15.6% (In reaction to earnings/guidance)
• $Apyx Medical (APYX.US)$ +8% (anno...
• $Kezar Life Sciences (KZR.US)$ +92% (announces positive top line results from the MISSION Phase 2 trial)
• $Sutro Biopharma (STRO.US)$ +24.5% (Sutro Biopharma and Astellas to collaborate to advance novel immunostimulatory antibody-drug conjugates)
• $Ceragon (CRNT.US)$ +17.7% (AVNW to acquire all shares of CRNT that it does not already own for $2.80/sh)
• $Trip.com (TCOM.US)$ +15.6% (In reaction to earnings/guidance)
• $Apyx Medical (APYX.US)$ +8% (anno...
22
2
Upgrades
• $CDW Corp (CDW.US)$: Stifel Upgrades to Buy from Hold - PT $210 (from $200)
• $Corteva (CTVA.US)$ : Loop Capital Upgrades to Buy from Hold - PT $69
• $CoreCivic, Inc. (CXW.US)$ : Wedbush Upgrades to Outperform from Neutral - PT $17 (from $10.85)
• $Delta Air Lines (DAL.US)$ : Barclays Upgrades to Overweight from Equalweight - PT $60 (from $42)
• $H.B. Fuller (FUL.US)$ : Baird Upgrades to Outperform from Neutral - PT $85
• $Huntington Ingalls Industries (HII.US)$ : Cowen U...
• $CDW Corp (CDW.US)$: Stifel Upgrades to Buy from Hold - PT $210 (from $200)
• $Corteva (CTVA.US)$ : Loop Capital Upgrades to Buy from Hold - PT $69
• $CoreCivic, Inc. (CXW.US)$ : Wedbush Upgrades to Outperform from Neutral - PT $17 (from $10.85)
• $Delta Air Lines (DAL.US)$ : Barclays Upgrades to Overweight from Equalweight - PT $60 (from $42)
• $H.B. Fuller (FUL.US)$ : Baird Upgrades to Outperform from Neutral - PT $85
• $Huntington Ingalls Industries (HII.US)$ : Cowen U...
19
No comment yet
Kraks : I don't understand how $Walgreens Boots Alliance (WBA.US)$ can gain from AI
Ni Niu : Good question, I wonder top.. Any shifu?